Olaparib Efficacy in Patients with Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

The authors presented exploratory analyses on the use of ctDNA testing as an additional method to identify castration-resistant prostate cancer patients with homologous recombination repair gene alterations who may be eligible for olaparib treatment.